KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacific Biosciences Of California (PACB) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Pacific Biosciences Of California (PACB) over the last 15 years, with Q3 2025 value amounting to $22.5 million.

  • Pacific Biosciences Of California's Cost of Revenue fell 2477.39% to $22.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $115.3 million, marking a year-over-year decrease of 1543.07%. This contributed to the annual value of $116.7 million for FY2024, which is 2098.88% down from last year.
  • According to the latest figures from Q3 2025, Pacific Biosciences Of California's Cost of Revenue is $22.5 million, which was down 2477.39% from $25.1 million recorded in Q2 2025.
  • In the past 5 years, Pacific Biosciences Of California's Cost of Revenue ranged from a high of $48.8 million in Q4 2023 and a low of $16.0 million during Q1 2021
  • In the last 5 years, Pacific Biosciences Of California's Cost of Revenue had a median value of $25.1 million in 2025 and averaged $26.4 million.
  • As far as peak fluctuations go, Pacific Biosciences Of California's Cost of Revenue skyrocketed by 11962.81% in 2023, and later tumbled by 4021.65% in 2024.
  • Pacific Biosciences Of California's Cost of Revenue (Quarter) stood at $19.3 million in 2021, then grew by 15.37% to $22.2 million in 2022, then soared by 119.63% to $48.8 million in 2023, then tumbled by 40.22% to $29.2 million in 2024, then decreased by 22.72% to $22.5 million in 2025.
  • Its Cost of Revenue was $22.5 million in Q3 2025, compared to $25.1 million in Q2 2025 and $38.5 million in Q1 2025.